Arabic Arabic English English French French German German
dark

HUYABIO Files an Investigational New Drug Application with the FDA for the Novel SHP2 Inhibitor HBI-2376

HUYABIO International announced today the filing of an investigational new drug application (IND) with the FDA for HBI-2376 along with Genhouse who has filed an IND with the Chinese Center for Drug Excellence CDE. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Departure of Founder and CEO Heightens Uncertainty for Galapagos

Next Post

Medivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818

Related Posts
Total
0
Share